Reply to author.

[1]  G. Maartens,et al.  A Randomized Controlled Trial of Intravenous N-acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Hsin-Jen Chen.  It is not a case-control study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[4]  G. D. Dal Pan,et al.  Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  E. Cox,et al.  The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. , 2009, The New England journal of medicine.

[6]  M. Ison,et al.  Response to several recent publications related to safety and efficacy of peramivir from the emergency use authorization experience. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.